Latest News
-
Saturday - September 28, 2019
Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer
79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications(1,2) / Similar ORR of 75% in patients with brain metastases(1), adding to the previously reported evidence for larotrectinib’s activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years(1) / Largest dataset with longest follow-up of any TRK inhibitor illustrates favorable safety profile across ages and tumor types(1) » more
-
Tuesday - September 24, 2019
Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases
Investment of over USD 30 million spanning five years to research and develop new treatments for chronic lung diseases / Joint lab to broaden Bayer’s presence in the Boston ecosystem » more
-
Monday - September 23, 2019
Not intended for U.S. and UK Media
Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EU
Precision oncology treatment Vitrakvi® (larotrectinib) approved for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Vitrakvi, which was exclusively designed to treat TRK fusion cancer, is the first therapy in the EU with a tumor-agnostic indication / Larotrectinib provides high response rates and durable responses in adults and children with TRK fusion cancer, including primary CNS tumors and brain metastases / In studies, larotrectinib demonstrated an overall response rate of 72% including 16% complete responses, with 75% of patients still on treatment after one year / Larotrectinib showed a favorable safety profile, with the majority of adverse events (AEs) being grade 1 or 2; only 3% of patients had to stop therapy due to treatment-emergent AEs » more
-
Friday - September 20, 2019
Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Bayer data at ESMO 2019 highlights innovation in cancer research
New data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer’s prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondrosarcoma to be highlighted in an oral presentation on September 30 » more
-
Tuesday - September 17, 2019
Not intended for U.S. and UK Media
Bayer and Informed Data Systems Inc. to develop One Drop digital therapeutics platform for multiple therapeutic areas
Equity stake in company through Series B financing of USD 20 million acquired / USD 10 million commercial licensing agreement for One Drop digital platform signed » more
-
Wednesday - September 11, 2019
Initiative offers financial support for novel approaches and enabling technologies in crop research
Bayer opens application window for Grants4Traits™ and Grants4Biologicals™ » more
-
Tuesday - September 10, 2019
Changes to Board of Management structure as of January 1, 2020:
Bayer reduces size of Board of Management from seven to five members » more
-
Tuesday - September 10, 2019
Bayer launches latest fungicide innovation, iblon™ technology
Isoflucypram, member of a newly introduced chemical subclass in the family of Succinate Dehydrogenase Inhibitors (SDHIs), is the core of iblon™ technology / iblon™ technology delivers excellent disease control leading to healthy-looking and consistently higher yielding cereal crops » more
-
Friday - September 6, 2019
Bayer showcases Root2Success for potato and sweet potato growers at congress in Rwanda:
Yields more than doubled during 4-year project with smallholder farmers » more
-
Thursday - September 5, 2019
Monsanto stakeholder lists: No evidence of illegal behaviour
Comprehensive investigation of the law firm Sidley Austin LLP completed and publicly available / Lists included almost 1,500 individuals in several European countries / Sidley Austin LLP assessed over 2.4 million documents – no “sensitive” information was / tracked » more
-
Tuesday - September 3, 2019
Bayer appoints Marianne De Backer Head of Pharmaceuticals Business Development & Licensing and Member of Executive Committee » more
-
Tuesday - September 3, 2019
Bayer Foundation creates EUR 20 million Social Innovation ecosystem fund to spur entrepreneurship for African smallholder farmers
EUR 3 million awarded today to four social innovators to generate entrepreneurial opportunities in agriculture and health for African smallholder farmers and increase their income / Social Innovation ecosystem is a key step towards Bayer’s goal to improve the living conditions of 100 million smallholder farmers including their family members by 2030 » more
-
Monday - September 2, 2019
Not intended for U.S. and UK Media - New guidelines from the European Society of Cardiology (ESC):
Xarelto™ 2.5 mg plus aspirin recommended for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromes
Clinical practice guidelines from the European Society of Cardiology (ESC) recommend Xarelto vascular dose (2.5 mg twice daily) plus aspirin low dose once daily in the management of patients with chronic coronary syndromes (CCS) as well as for patients with diabetes and lower extremity arterial disease / New guidelines include a change in nomenclature from ‘stable coronary artery disease’ to ‘chronic coronary syndromes’ to better reflect the continuous high risk of heart attacks, strokes and death within this patient population » more
-
Monday - September 2, 2019
Bayer completes sale of iconic Coppertone™ brand to Beiersdorf
Divestiture enables Bayer to focus on core OTC business » more
-
Wednesday - August 28, 2019
Bayer Animal Health launches Drontal™ Plus Tasty in China
Since its launch in China 10 years ago Drontal has a leading position in the veterinary channel / Drontal™ Plus Tasty replaces Drontal™ Plus Flavor with new innovative key features » more
-
Tuesday - August 20, 2019
Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollars
Exit of Animal Health business completes the series of portfolio measures initiated by Bayer in November 2018 ahead of announced schedule / Enhances Bayer’s focus as a global leader in life sciences » more
-
Thursday - August 15, 2019
Bayer provides produce growers with holistic approach to field challenges during first ever Agriculture and Innovation Showcase
De Ruiter and Seminis seed brands discuss sustainable and tailored solutions / Industry collaborators demonstrate new advances in digital automation technology » more
-
Thursday - August 8, 2019
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year / BlueRock Therapeutics to continue to operate as an independent company » more
-
Tuesday - August 6, 2019
Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real Assets
Currenta valued with an attractive enterprise value of EUR 3.5 billion (100%) » more
-
Wednesday - July 31, 2019
Not intended for U.S. and UK Media
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer
Darolutamide was approved in the U.S. under the FDA Priority Review designation; approval granted three months ahead of target FDA action date / Approval based on Phase III ARAMIS trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, February 27, 2020
Financial News Conference on the Full Year 2019 Results
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV